KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to 0.61%.

  • Recursion Pharmaceuticals' Return on Capital Employed rose 100.0% to 0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61%, marking a year-over-year increase of 100.0%. This contributed to the annual value of 0.55% for FY2024, which is 400.0% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.61% for Q3 2025, which was up 100.0% from 0.57% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.23% during Q3 2021, with a 5-year trough of 0.71% in Q1 2024.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.46% (2025), whereas its average is 0.48%.
  • In the last 5 years, Recursion Pharmaceuticals' Return on Capital Employed tumbled by -2500bps in 2024 and then surged by 2400bps in 2025.
  • Recursion Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.31% in 2021, then tumbled by -42bps to 0.44% in 2022, then plummeted by -44bps to 0.64% in 2023, then rose by 17bps to 0.53% in 2024, then decreased by -14bps to 0.61% in 2025.
  • Its Return on Capital Employed was 0.61% in Q3 2025, compared to 0.57% in Q2 2025 and 0.46% in Q1 2025.